Phase 3 trials of DOACs, such as the RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy),7 ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation),8, 9, 10, 11 and ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48)12 trials, indicate that D-dimer, cardiac troponin, and N-terminal pro–B-type natriuretic peptide are predictors of stroke and mortality that significantly enhance predictive ability when added individually to clinical risk scores. The gene discussed is F10; the disease is atrial fibrillation.